Related Experiment Video
Updated: Mar 26, 2026
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
24.5K
Post-gastric bypass hypoglycaemia: a review.
Prapimporn C Shantavasinkul1, Alfonso Torquati2, Leonor Corsino3
1Division of Nutrition and Biochemical Medicine, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Clinical Endocrinology
|February 4, 2016
Summary
Postbariatric surgery hypoglycemia, often following Roux-en-Y gastric bypass, is an increasing concern. Management typically involves dietary changes, though further research is needed for optimal treatment.
Area of Science:
- Endocrinology
- Bariatric Surgery Outcomes
- Metabolic Disorders
Background:
- Bariatric surgery effectively treats severe obesity and related conditions.
- Postbariatric surgery hypoglycemia is an emerging complication, particularly after Roux-en-Y gastric bypass (RYGB).
- The exact causes of this condition are still under investigation.
Purpose of the Study:
- To review the current understanding of postbariatric surgery hypoglycemia.
- To discuss potential pathophysiological mechanisms.
- To outline current diagnostic and management strategies.
Main Methods:
- Literature review of studies on postbariatric surgery hypoglycemia.
- Analysis of proposed mechanisms, including incretin hormone secretion (e.g., GLP-1) and hyperinsulinemia.
- Evaluation of dietary and medical interventions.
Main Results:
- Postprandial hyperinsulinemia and elevated glucagon-like peptide-1 (GLP-1) secretion are implicated in hypoglycemia development.
- Symptoms typically occur 1-3 hours after meals, exacerbated by carbohydrate-rich foods.
- Dietary modifications, such as carbohydrate restriction, are the primary management approach.
Conclusions:
- Postbariatric surgery hypoglycemia is a complex condition linked to altered post-meal hormonal responses.
- Dietary management is often effective, but some patients may require further intervention.
- Further clinical trials are essential to elucidate pathophysiology and optimize treatment strategies.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:14SBAR II: Application of SBAR
6.8K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
6.8K
01:06Oral Hypoglycemic Agents: Glinides
929
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
929
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
845
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
845
01:20Pathophysiology of Diabetes
4.3K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.3K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
919
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
919